Kips Bay Medical (NASDAQ: KIPS) today announced that the United States Patent and Trademark Office (USPTO) has issued to the Company patent number 7,998,188, titled “Compliant Blood Vessel Graft,” which includes eleven permitted claims covering the Company’s core eSVS ® MESH technology, and represents the first patent obtained in the United States covering this technology. The USPTO has also issued a Notice of Allowance approving a second patent application, titled “Compliant Venous Stent,” which includes three claims related to the eSVS MESH design.
“This is great news for the Company,” stated Manny Villafaña, Chairman and Chief Executive Officer. “We believe that the issuance of this patent and the approval of this patent application provide the foundation for very strong and broad-based protection for our eSVS MESH. These are important milestones in the development and growth of our intellectual property portfolio and securing our leadership position in cardiovascular bypass surgery.”
At present, the Company possesses issued patents in Japan and Canada covering the eSVS MESH. In addition, it has received a Notice of Allowance from the European Patent Office and is presently engaged in the grant phase to validate the European patent in eight European Countries. The company is pursuing additional patent applications which are pending in the United States and in strategic countries world-wide.
About Kips Bay MedicalKips Bay Medical, Inc., founded in 2007 and headquartered in Minneapolis, Minnesota, is a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, or eSVS MESH for use in coronary artery bypass grafting surgery. Our eSVS MESH is a nitinol mesh sleeve that, when placed over a saphenous vein graft during CABG surgery, is designed to improve the structural characteristics and long-term performance of the saphenous vein graft. Additional information about Kips Bay Medical, Inc. can be found at www.kipsbaymedical.com.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV